Related Experiment Video
Updated: Sep 16, 2025
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
A bibliometric analysis of targeted therapy cardiotoxicity research in cancer patients (2004-2024)
Guoming Chen1, Guang Chen1, Huiping Zhou2
1School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Background:
The management of long-term cardiotoxicity has become increasingly challenging despite the growing utilization of targeted therapies to enhance progression-free and overall survival rates. Although there is a proliferation of literature on the incidence and mechanisms of cardiotoxicity induced by targeted therapies, no comprehensive analysis of the publication landscape has addressed the unmet medical needs in this area. This study aimed to characterize global research trends, map collaborative networks, and highlight unresolved issues in cardiotoxicity management to fill the gaps in this field and inform future research.
Method:
This study conducted a bibliometric analysis of articles concerning targeted therapy-induced cardiotoxicity published between 2004 and 2024 from the Web of Science (WOS) database using VOSviewer and CiteSpace. A total of 1,054 publications from 71 countries/regions and 2,058 research institutions were examined.
Result:
The number of publications has shown an average annual increase of 50 articles from 2004 to 2024. Key research topics in targeted therapy cardiotoxicity encompass breast cancer, heart failure, and drug delivery. The most cited publication is a guideline titled "Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline." These results indicate a rising trend in research on tumor-targeted therapy cardiotoxicity over the past two decades. Recent research trends and future directions primarily focus on two key areas: the development of novel nanocarriers aims to enhance therapeutic efficacy while reducing cardiac toxicity, and the exploration of mechanisms underlying cardiac injury caused by targeted therapeutic drugs is crucial, along with the investigates drug interventions to counter these mechanisms or the application of alternative techniques for the prevention, alleviation, or treatment of cardiac injury.
Conclusion:
This study provides a comprehensive overview of targeted therapy-induced cardiotoxicity research from 2004 to 2024. By identifying key research priorities, this analysis addresses critical gaps in current knowledge. Future endeavors should prioritize translational innovations and multidisciplinary clinical frameworks to enhance therapeutic safety.
Insights
Research on cardiotoxicity from targeted cancer therapies is increasing, with a focus on novel nanocarriers and understanding drug mechanisms. This study identifies research gaps to improve patient outcomes and therapeutic safety.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
- Bibliometrics
Background:
- Cardiotoxicity management is challenging with targeted therapies.
- Literature on incidence and mechanisms of cardiotoxicity is growing.
- A comprehensive analysis of research trends and unmet needs is lacking.
Purpose of the Study:
- To characterize global research trends in cardiotoxicity induced by targeted therapies.
- To map collaborative networks in this research area.
- To highlight unresolved issues and inform future research directions.
Main Methods:
- Bibliometric analysis of publications from 2004-2024.
- Data sourced from the Web of Science (WOS) database.
- Analysis tools included VOSviewer and CiteSpace.
Main Results:
- A consistent annual increase of 50 publications from 2004-2024.
- Key research areas include breast cancer, heart failure, and drug delivery.
- Future research focuses on nanocarriers, understanding cardiac injury mechanisms, and developing interventions.
Conclusions:
- This study offers a comprehensive overview of targeted therapy-induced cardiotoxicity research.
- Identified research priorities address critical knowledge gaps.
- Future work should emphasize translational innovations and multidisciplinary clinical frameworks for enhanced safety.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:34Inhibition of Cdk Activity
01:21Cancer Survival Analysis